CCM
EW icon

Copernicus Capital Management’s Edwards Lifesciences EW Stock Holding History

Copernicus Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-97,632
Closed -$5.67M – 16
2018
Q3 		$5.67M Sell
97,632
-76,368
-44% -$3.74M 5.32% 7
2018
Q2 		$8.44M Buy
174,000
+83,526
+92% +$3.9M 6.13% 8
2018
Q1 		$4.21M Sell
90,474
-83,556
-48% -$3.63M 3.35% 15
2017
Q4 		$6.54M Buy
+174,030
New +$6.39M 4.87% 8

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Copernicus Capital Management's EW Position: Q4 2018 in Review

Copernicus Capital Management sold out of Edwards Lifesciences (EW) in Q4 2018, closing a stake of 97,632 shares — an estimated $5.67M sold.

Copernicus Capital Management first reported a position in EW in Q4 2017 and held it in 4 quarters. The position peaked at $8.44M in Q2 2018. 874 funds tracked by Wall St. Rank hold EW as of Q4 2018.

  • Copernicus Capital Management reported no remaining Edwards Lifesciences position as of Q4 2018 after selling out during the quarter.
  • Copernicus Capital Management sold 97,632 Edwards Lifesciences shares in Q4 2018, an estimated $5.67M.
  • Copernicus Capital Management first reported a position in Edwards Lifesciences in Q4 2017 and held it in 4 quarters.
  • Copernicus Capital Management's Edwards Lifesciences position peaked at $8.44M in Q2 2018.
  • 874 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2018.

Based on Copernicus Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.